The Effects of Pentoxifylline on PAI-1 in an Obese Population
Completed · Phase 4 · Has a placebo group
Conditions studied: Obesity
In brief
PAI-1 is elevated in obese individuals. TNF-alpha, an inflammatory mediator is believed to play a role in obesity mediated elevations in PAI-1 levels. TNF-alpha blockade with antibodies and the drug pentoxifylline have been shown to lower PAI-1 levels in animal models. This study tests the hypothesis that pentoxifylline will lower PAI-1 levels in human subjects.
Key facts
- Study ID
- NCT00770328
- Run by
- Vanderbilt University
- People needed
- 37
- Starts
- 2003-05-01
- Expected to finish
- 2009-06-01
- Last updated by the study team
- 2017-11-30
Who can join
Age: 21 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- Vanderbilt University Medical Center — Nashville, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.